INTRODUCTION
Short tandem repeat (STRs) markers are used in cases regarding human identification of maternity, paternity, and kinship relationship. Also, they can be used in on-co-hematology chimerism monitoring in patients after allogeneic stem cell transplantation (allo-SCT) [1] . In the last three decades, transplantation of stem cell peripheral blood and bone marrow transplantation have become an important medical procedure in the treatment of malignant and non-malignant hematological diseases in children and adults [2, 3] . The allo-SCT represents an important modality of treatment in case of patients with severe hematological disorders [4] . After transplantation, it is important to know if the newly developed hematopoietic system has donor or recipient origin. In this case, the genetic analysis which investigates the origin of the genotype are known as ''chimerism''. The word ''chimera'' comes from the Greek mythology where Homer describes a monster with a lion head, a body of a goat and a tail of a serpent [5] . The term ''chimerism'' was introduced in medicine for the first time in 1951 by Anderson et al. [6] . Five years later, in 1956, Ford used this term in the transplantation field [7] . Chimerism represents the percentage of donor derived blood after the allo-SCT and has a prognostic value for diseases relapse [8] [9] [10] [11] . Short tandem repeats (STR) are used to monitor the hematopoietic cell chimerism during the post-transplant period [12] . For post-transplant chimerism monitoring, the laboratory protocol, after the DNA isolation from the biological samples, follows the next steps: DNA quantification, amplification by the polymerase chain reaction (PCR) using the STR markers, and visualisation of the PCR products by capillary electrophoresis [13] . After allo-HSC transplantation in many cases was observed that hematopoiesis of the recipient and donor coexist in the recipients. This situation is called ''mixed chimerism'' (MC). In this MC, in the post-transplant sample both donor and recipient genotypes are present. If after allo-HSC all the hematopoietic cells have donor's origin, it is called ''complete chimerism'' (CC). In CC, in the post-transplant sample only the donor's DNA is present. Studies have demonstrated that the posttransplant chimerism has a dynamic evolution [14, 15] . In allo-HSC the biological samples used for molecular post-transplant monitoring are peripheral blood collected on ethylenediaminetetraacetic acid (EDTA) and bone marrow aspirate. In the pre-transplantation phase, when a compatible donor exists, buccal swabs and peripheral blood samples collected on EDTA are sent to the laboratory of forensic genetics to obtain the genetic profiles of each person. The obtained genotypes are called ''reference samples''. The diagnosis of ALL, is based on cell morphology and cytochemistry. In addition to these, other laboratory investigations are needed such as: cytogenetic testing (conventional and molecular-fluorescence in situ hybridisation (FISH), immunophenotyping, and molecular analysis [16] . In this article we present the advantages of STR markers in chimerism monitoring of a girl, diagnosed with ALL who underwent two allo-HSCT.
MATERIALS AND METHODS
The HSC donor was found in the German Registry of hematopoietic stem cell donors. After the histocompatibility was found between the donor and the recipient, peripheral blood samples from the donor and the recipient were collected on EDTA. Also, epithelial cells from the inner cheeck were collected from both by buccal swabbing with 4N6FLOQSwabs™ (Copan, Italy) [17] . The study protocol was approved by the ethics committee of ''Victor Babes'' University of Medicine and Pharmacy, Timisoara, Romania. It was conducted in accordance to the principles of the Declaration of Helsinki. The biological samples were collected after the parents of the child gave their consent for this procedure.
Extraction of DNA from buccal epithelial cells and peripheral blood samples
The DNA from the epithelial cells from inner cheeks was isolated using the Pure Link Genomic DNA kit (Invitrogen, USA), following the protocol for human buccal swabs. To isolate the DNA from the blood samples, Pure Link Genomic DNA kit (Invitrogen, USA) was used, following the protocol for blood [18] .
Quantification of the DNA samples from the donor and recipient
For the quantification of the extracted DNA samples, Quantifiler Human DNA (Thermo Fischer, USA) was used. The DNA quantification was performed on a 7500 Real-time PCR (Applied Biosystems, USA). Electropherograms of the reference DNA profiles from both donor and recipient are presented in Figure 1 and Figure 2 . The reference DNA profiles are presented in Table 2 . The DNA concentrations of the reference samples from the donor and recipient are presented in Table 1 .
Amplification of the DNA products
The Amp FlSTR NGM SElect PCR amplification kit (Thermo Fischer, USA) was used for the amplification of the DNA reference samples from both donor and recipient. The loci included in the AmpFlSTR NGM Select PCR amplification kit are as follows: D10S1248; Vwa; D16S539; D2S1338; D8S1179; D21S11; D18S51; D22S1045; D19S433; TH01; FGA; D2S441; D3S1358; D1S1656; D12S391; SE33; Amelogenin. For the amplification, 10 µL of AmpFlSTR NGM Select Master Mix and 5 µL of AmpFlSTR NGM Select Primer Set were used for each sample, according to the producer's recommendations [19] . Further, the final reaction volume was 25 µL, consisting in 15 µL of reaction mixture and 10 µL of DNA solution. The final reaction volume of 25 µL was added in PCR tubes. The tubes were centrifuged at 3,000 rpm for 20 seconds according to the producers' recommendations to remove the bubbles. For the PCR amplification, the initial incubation step was 11 minutes at a temperature (T) = 95°C. The incubation step was followed by 29 cycles consisting in 2 steps: denature: 20 minutes at a T = 94°C and annealing 3 minutes at T = 59°C. A final extension of 10 minutes at T = 60°C and a final hold at T = 4°C indefinite.
Electrophoresis of the PCR products
The PCR products were run on a 3500 Genetic Analyzer (Applied Biosystems, USA) to obtain the genetic profiles. According to the manufacturer's instructions we added 1 µL of the amplified product (DNA sample and allelic ladder) to the mix which contained: 9.5 µL of Hi-Di Formamide (Applied Biosystems, USA) and 0.5 µL of Gene Scan 600 LIZ (Applied Biosystems, USA). The reaction plate was heated in a thermal cycler for 3 minutes at a T = 95°C followed by the denaturation step of 3 minutes at T = -20°C. The Gene Mapper ID-X Software version 1.4 (Applied Biosystems, USA) was used for the visualization of the DNA profiles.
RESULTS
One month after the first allo-HSC transplant the first chimerism test was done. The condition for this was a neutrophil count of 500 for 3 consecutive days. A mixed chimerism consisting in both donor and recipient genotypes was obtained. In this case, the recipient's cells were 68% compared to the donor's 32% ( Figure  3 ).
Figure 3
On the 45th day post-transplantation, a new transplant with the donor's cells was performed. Fifteen days after the second transplantation a new chimerism test was performed. This time, the chimerism value was 91% donor's cells in recipient's blood (Figure 4 ).
Figure 4
On the 21st day from the 2nd transplantation, another chimerism test was performed from blood. This time, there was a complete chimerism, showing the donor's genotype on the electrophoresis ( Figure 5 ).
Figure 5
The values of the percentages from the donor and recipient DNA were calculated for each of the individual proportions of the donor and recipient peak areas [20] . 
DISSCUSION
In patients with ALL, many studies have shown that those who present an increased chimerism are at risk of relapse and graft rejection [21] [22] [23] . Currently, the gold standard method for chimerism monitoring is the analysis using multiplex STR markers by PCR method, followed by capillary electrophoresis [24] . Serial chimerism monitoring in allo-HSCT using STR markers helps in identifying the patients who present the risk of relapse or graft rejection [25] . Thus it is important to identify those patients early who have increased risk for relapse, because immunotherapy has to be administered to them in time, as prophylaxis. Patients who are at risk of relapse can be identified early, by performing frequent chimersim monitoring using multiplex STR markers and semiquantitative PCR method. Using multiplex STR markers, it has been demonstrated that chimerism analysis should be performed based on a short time interval, thus suggesting that early and frequent testing for chimerism can aid in identifying those patients who require an increased immunotherapy because they are at risk of graft rejection or relapse [26] [27] [28] .
CONCLUSION
We conclude that in patients with ALL, early and serial chimerism monitoring using multiplex STR markers represents an important tool in identifying those who are at risk of relapse after allo-HSCT.
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